Difference between revisions of "Part:BBa K4165154"
| Line 8: | Line 8: | ||
The amino acid sequence of the MM3 peptide is DPLKARHTSVWY. It is the L-enantiomeric peptide of MMD3 (BBa_K4165141). Its charge is +1, hydrophobicity is 41 %, molecular weight is 1472.65 Da. MM3 can reduce aggregates of full-length tau when mixed in ratio 1:10 and 1:5 and PHF* (VQIINK) but not PHF (VQIVYK). | The amino acid sequence of the MM3 peptide is DPLKARHTSVWY. It is the L-enantiomeric peptide of MMD3 (BBa_K4165141). Its charge is +1, hydrophobicity is 41 %, molecular weight is 1472.65 Da. MM3 can reduce aggregates of full-length tau when mixed in ratio 1:10 and 1:5 and PHF* (VQIINK) but not PHF (VQIVYK). | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
===Dry Lab=== | ===Dry Lab=== | ||
| Line 37: | Line 30: | ||
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/mm3-qa.png" style="margin-left:75px;" alt="" width="800" /></p> | <p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/mm3-qa.png" style="margin-left:75px;" alt="" width="800" /></p> | ||
</html> | </html> | ||
| + | |||
| + | <!-- --> | ||
| + | <span class='h3bb'> <p style=" font-weight: bold; font-size:17px;"> Sequence and Features</p> </span> | ||
| + | <partinfo>BBa_K4165154 SequenceAndFeatures</partinfo> | ||
Revision as of 13:52, 6 October 2022
MM3
Tau binding peptide targeting the PHF seed of Tau
Usage and Biology
The amino acid sequence of the MM3 peptide is DPLKARHTSVWY. It is the L-enantiomeric peptide of MMD3 (BBa_K4165141). Its charge is +1, hydrophobicity is 41 %, molecular weight is 1472.65 Da. MM3 can reduce aggregates of full-length tau when mixed in ratio 1:10 and 1:5 and PHF* (VQIINK) but not PHF (VQIVYK).
Dry Lab
Modeling
MM3 is modeled by Apptest, ITASSER and TrRosetta, best model obtained from trrosetta.
Figure 1.: Predicted 3D structure of Synthetic peptide MM3.
Table 1: Quality assessment parameters of MM3 model.
Sequence and Features
Assembly Compatibility:
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
References
1. Malhis, M. (2021). Selection and characterization of D-enantiomeric peptides for the investigation of options for therapy and diagnosis of Alzheimer's disease . University of Bayreuth (Germany).